Converted by EDGARwiz



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

________________________________


FORM 8-K


CURRENT REPORT


PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934


DATE OF REPORT (Date of earliest event reported):  November 13, 2012


IGI LABORATORIES, INC.

(Exact name of registrant as specified in charter)


DELAWARE
(State or Other Jurisdiction of
Incorporation)

001-08568
(Commission
file number)

01-0355758
(I.R.S. Employer
Identification
Number)

105 Lincoln Avenue
Buena, New Jersey 08310
(Address of principal executive offices) (Zip Code)


(856) 697-1441
(Registrant’s telephone number, including area code)


Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))







Item 2.02.   Results of Operations and Financial Condition.


On November 13, 2012, IGI Laboratories, Inc. (the "Company") issued a press release announcing the Company's earnings for the third quarter ended September 30, 2012 and certain other information. A copy of the press release is attached hereto as Exhibit 99.1.  The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, except as shall otherwise be expressly set forth by specific reference in such filing.


Item 9.01.   Financial Statements and Exhibits.


(d)  The following exhibits are furnished with this Form 8-K:


Exhibit No.

 

Description

 

 

 

99.1

 

Press Release of IGI Laboratories, Inc. dated November 13, 2012



2




SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


IGI LABORATORIES, INC.


Date: November 13, 2012

By: /s/ Jenniffer Collins

 

Name:  

Jenniffer Collins   

 

Title:  

Chief Financial Officer



3




EXHIBIT INDEX


Exhibit No.

 

Description

 

 

 

99.1

 

Press Release of IGI Laboratories, Inc. dated November 13, 2012




4